Скачать или смотреть Australia Issues Mental Health Warning on Ozempic and Weight-Loss Drugs

Australia’s Therapeutic Goods Administration (TGA) has released new safety warnings about popular diabetes and weight-loss drugs, including Ozempic, Wegovy, Saxenda, Trulicity, and Mounjaro.
The regulator advises healthcare professionals to closely monitor patients for signs of depression, suicidal thoughts, or changes in mood linked to GLP-1 receptor agonists. The TGA also warns that Mounjaro could reduce the effectiveness of oral contraceptives when starting or increasing doses. Women are advised to use backup contraception or switch to non-oral options during this period.
This major update raises awareness about the mental health impact and reproductive risks associated with new weight-loss medicines. Stay informed about what this means for patients and doctors in Australia’s growing use of injectable weight-loss treatments.